The primary aim of this study was to evaluate the ability of integrin αvβ6, carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), Cathepsin E (Cath E), EGFR, hepatocyte growth factor receptor (c-MET), thymocyte differentiation antigen 1 (Thy1), and uPAR as targets to differentiate between PDAC, CP and normal pancreatic tissue for tumor-specific imaging and for the potential to develop clinically translatable imaging agents targeting these markers. The gene discussed is MET; the disease is neoplasm.